// App-Quantinova.ai

Sa1106 : Adalimumab Monotherapy Versus Combination Therapy With Adalimumab and Immunomodulators for Crohn's Disease: a Meta-Analysis

Researchers

Presenter

  • Talal Al-Taweel

Principal Investigators

  • Mohammad Yaghoobi

  • Alain Bitton

  • Peter L. Lakatos

  • Shomron Ben-Horin

  • Ernest G. Seidman

  • Waqqas Afif

Medical Centers

  • Stroke Center, Sheba Medical Center, Tel Hashomer, Israel

  • First Department of Internal Medicine, Semmelweis University, Budapest, Hungary

  • Medicine & Pediatrics, GI Division, McGill University Health Center, Montreal, Quebec, Canada

Locations

  • United States

  • Canada

  • Hungary

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • N/A

Drug/Treatment

  • Oraprine

  • Adalimumab

  • Infliximab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved